Aurinia Pharmaceuticals Inc.

Nearly all revenue comes from direct sales of one approved drug in its home market, with a much smaller stream of licensing, milestone and royalty payments from the partner that sells the same drug elsewhere. Revenue has risen every year across recent years and current margins sit at the high end of its industry, though net income was negative in some earlier years within that same stretch.

Multiple margin and return measures sit at the upper end of its industry's range alongside multi-year revenue growth, suggesting that once a therapy is approved and prescribed, additional sales convert to profit at a high rate rather than requiring proportional new spending. This points to growth coming from widening the prescriber and patient base for its approved therapy and from clearing new approval gates for additional therapies rather than from expanding physical capacity, and this profitable pattern appears to be a comparatively recent state rather than a constant across its history.

Its own filings name a sole contract manufacturer for its drug's active ingredient and a separate sole manufacturer that turns that ingredient into finished capsules, plus an unnamed supplier for final packaging, alongside outside clinical-trial and research partners needed to advance therapies still awaiting approval. It also depends on a partner company to sell its approved product outside its home market, and CompanyGraph's industry mapping separately places it downstream of a small number of supplying industries.

Its direct customers are a small, unnamed set of specialty pharmacies and distributors in its home market, plus a named partner company that resells its approved product in other countries under a licensing arrangement. CompanyGraph's industry mapping also places it upstream of a wider set of industries it supplies, and the patients who ultimately use its product depend on insurers and government health programs to make treatment affordable.

CompanyGraph places this company within a shape shared by many other businesses operating under the same approval-gated model, so the underlying business model is not unusual on its own. Within that shape, the company itself describes its approved therapy as the only oral option of its kind cleared by regulators for its target condition, an account it gives of its own position rather than a measurement CompanyGraph has independently verified.

The company's own filings tie further growth to whether prescribers change existing treatment practices in its favor, and separately list reimbursement decisions by insurers and government payors, new regulatory approvals, clinical-trial enrollment, uninterrupted supply from its contract manufacturers, and its ability to hire specialized staff as factors that could cap growth. It also states that its commercial results depend substantially on a single approved product, so that product's fate stands in for the company's near-term prospects as a whole.

The company's own filings name dependence on the commercial success of its single approved product as the first risk they disclose, and that product's supply runs through sole, named contract manufacturers for its active ingredient and its capsule form before reaching patients through a concentrated set of specialty channels in one home market. The regulatory exclusivity that protects this product from generic competition is currently being contested through litigation filed by multiple companies seeking to sell generic versions.

Its approved product remains subject to ongoing oversight across its full lifecycle by its home regulator, alongside a further set of national and international regulators and agencies named in its own filings. It also names active patent litigation against multiple companies seeking to sell generic versions of its product, along with possible tariffs on pharmaceutical imports and a currency exposure tied to fixed payments owed to an overseas manufacturing partner.